| Date and Time | Title | |
|---|---|---|
| Oct 29, 2021 12:45pm - 1:45pm (Eastern) | Resolving Therapeutic Inertia Using Actionable CGM Guidance The progressive nature of type 2 diabetes changes diabetes management over time in a variety of ways and is different for each person living with diabetes. Continuous glucose monitoring (CGM) provides a visual context to an individual’s current time-in-range and helps both the person and the healthcare professional identify areas to improve. This presentation will review the limitations of both A1C and blood glucose monitoring while highlighting the benefits of the Dexcom G6 real-time CGM system and Dexcom G6 Professional system in type 2 diabetes management. You will also learn to interpret Dexcom CLARITY reports through patient case studies, and how CLARITY data can be used for clinical guidance and therapeutic intervention. Learn to use CGM data and reports to inform treatment decisions via case studies Sponsored by Dexcom This is a Non CME/CE Presentation. |  |
| Oct 26, 2022 7:00am - 10:30am (Central) | Session I: Breast Cancer Risk Assessment and Screening x:xx pm CT | Session | 69 days to start |
| Oct 26, 2022 11:35am - 2:25pm (Central) | Session II: PET Imaging and Beyond x:xx am | Session | 69 days to start |
| Oct 26, 2022 4:00pm - 5:30pm (Central) | Session III: The Reading Room x:xx pm | Session | 69 days to start |
| Oct 27, 2022 8:10am - 10:15am (Central) | Session IV: Early Disease Considerations in HR-Positive Breast Cancer x:xx pm | Session | 70 days to start |
| Oct 27, 2022 12:55pm - 3:00pm (Central) | Session V: Metastatic Disease Considerations in HR-Positive Breast Cancer x:xx pm | Session | 70 days to start |
| Oct 27, 2022 3:10pm - 5:15pm (Central) | Session VI: Special Topics in HR-Positive Breast Cancer x:xx pm | Session | 70 days to start |
| Oct 28, 2022 8:10am - 10:15am (Central) | Session VII: Early Disease Considerations in HER2-Positive Breast Cancer x:xx pm | Session | 71 days to start |
| Oct 28, 2022 12:55pm - 3:00pm (Central) | Session VIII: Metastatic Disease Consderations in HER2-Positive Breast Cancer x:xx pm | Session | 71 days to start |
| Oct 28, 2022 3:10pm - 5:15pm (Central) | Session IX: Special Topics in HER2-Positive Breast Cancer x:xx pm | Session | 71 days to start |
| Oct 29, 2022 7:00am - 9:05am (Central) | Session X: Early Disease Considerations in Triple Negative Breast Cancer x:xx pm | Session | 72 days to start |
| Oct 29, 2022 10:30am - 1:00pm (Central) | Session XI: Metastatic Disease Considerations in Triple Negative Breast Cancer x:xx pm | Session | 72 days to start |
| Apr 7, 2023 11:00am - 12:00pm (Eastern) | Sample Live Non-CME/CE Bonus Presentation Join us to learn more about smart insulin therapy featuring InPen™ Smart Insulin Pen. Topics of discussion will include:Building a data driven care approach with smart insulin pens to address the challenges of insulin therapy; How to have productive conversations with your insulin therapy patients using the InPen™ Insights Report; Putting it all together: Case study Sponsored by Medtronic This is a Non CME/CE Presentation. | 232 days to start |
| Aug 4, 2023 4:30pm - 5:00pm (Eastern) | Visit Exhibit and Poster Halls Click HERE to visit the exhibit hall. Click HERE to visit the poster hall. | 351 days to start |
| Aug 4, 2023 6:30pm - 7:45pm (Eastern) | Sample CME/CE Independent Symposium: Title Goes Here Moderator: Seth J. Baum, MD Program Description: Put this here if applicable. If there is not one, then just remove this. 1 Additional hour of CME credit Supported by an independent educational grant from Esperion Therapeutics ACCREDITATION STATEMENT
For Physicians | 351 days to start |
 | |||
Agenda
|
|
